CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 17, 2016
Result type: Reports
Project Number: SR0484-000
Product Line: Reimbursement Review

Generic Name: Brivaracetam

Brand Name: Brivlera

Manufacturer: UCB Canada Inc.

Therapeutic Area: Epilepsy, partial-onset seizures

Indications: Epilepsy, partial-onset seizures

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 25, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions